Biodexa Pharmaceuticals (BDRX) Gains from Sales and Divestitures (2018)
Biodexa Pharmaceuticals (BDRX) posted Gains from Sales and Divestitures of $11.9 million for Q4 2018.
Biodexa Pharmaceuticals (BDRX) Gains from Sales and Divestitures (2018) Analysis & Trends
Biodexa Pharmaceuticals has reported Gains from Sales and Divestitures for 1 years, with the latest figure at $11.9 million in Q4 2018.
- Quarterly Gains from Sales and Divestitures changed N/A year-over-year to $11.9 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $11.9 million (changed N/A YoY) and the FY2019 annual result came in at $1.2 million, down 90.22% from the prior year.
- Gains from Sales and Divestitures steadied at $11.9 million in Q4 2018 per BDRX's latest filing.
- Over five years, Gains from Sales and Divestitures peaked at $11.9 million in Q4 2018 and troughed at $11.9 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 11.91 Mn |
| Dec 31, 2018 | 11.91 Mn |